Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

Related Content:

Mayo ClinicOncLive TVHematologic OncologyNon-Hodgkin LymphomaChronic Lymphocytic Leukemia
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma
Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer